These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 34560967)

  • 1. Oral delivery of infliximab using nano-in-microparticles for the treatment of inflammatory bowel disease.
    Li X; Yu M; Zhu Z; Lu C; Jin M; Rao Y; Zhao Q; Lu X; Yu C
    Carbohydr Polym; 2021 Dec; 273():118556. PubMed ID: 34560967
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Nanocomposites-based targeted oral drug delivery systems with infliximab in a murine colitis model.
    Kim JM; Kim DH; Park HJ; Ma HW; Park IS; Son M; Ro SY; Hong S; Han HK; Lim SJ; Kim SW; Cheon JH
    J Nanobiotechnology; 2020 Sep; 18(1):133. PubMed ID: 32933548
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Chitosan oligosaccharide as potential therapy of inflammatory bowel disease: therapeutic efficacy and possible mechanisms of action.
    Yousef M; Pichyangkura R; Soodvilai S; Chatsudthipong V; Muanprasat C
    Pharmacol Res; 2012 Jul; 66(1):66-79. PubMed ID: 22475725
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Carboxymethyl chitosan microspheres loaded hyaluronic acid/gelatin hydrogels for controlled drug delivery and the treatment of inflammatory bowel disease.
    Zhang S; Kang L; Hu S; Hu J; Fu Y; Hu Y; Yang X
    Int J Biol Macromol; 2021 Jan; 167():1598-1612. PubMed ID: 33220374
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Alginate/chitosan microparticles for gastric passage and intestinal release of therapeutic protein nanoparticles.
    Ling K; Wu H; Neish AS; Champion JA
    J Control Release; 2019 Feb; 295():174-186. PubMed ID: 30557649
    [TBL] [Abstract][Full Text] [Related]  

  • 6. PEG-functionalized microparticles selectively target inflamed mucosa in inflammatory bowel disease.
    Lautenschläger C; Schmidt C; Lehr CM; Fischer D; Stallmach A
    Eur J Pharm Biopharm; 2013 Nov; 85(3 Pt A):578-86. PubMed ID: 24084650
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Impact of PEGylation on an antibody-loaded nanoparticle-based drug delivery system for the treatment of inflammatory bowel disease.
    Shrestha N; Xu Y; Prévost JRC; McCartney F; Brayden D; Frédérick R; Beloqui A; Préat V
    Acta Biomater; 2022 Mar; 140():561-572. PubMed ID: 34923097
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Infliximab-Tumor Necrosis Factor Complexes Elicit Formation of Anti-Drug Antibodies.
    Bar-Yoseph H; Pressman S; Blatt A; Gerassy Vainberg S; Maimon N; Starosvetsky E; Ungar B; Ben-Horin S; Shen-Orr SS; Chowers Y;
    Gastroenterology; 2019 Nov; 157(5):1338-1351.e8. PubMed ID: 31401142
    [TBL] [Abstract][Full Text] [Related]  

  • 9. AVX-470: a novel oral anti-TNF antibody with therapeutic potential in inflammatory bowel disease.
    Bhol KC; Tracey DE; Lemos BR; Lyng GD; Erlich EC; Keane DM; Quesenberry MS; Holdorf AD; Schlehuber LD; Clark SA; Fox BS
    Inflamm Bowel Dis; 2013 Oct; 19(11):2273-81. PubMed ID: 23949620
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Colon targeted oral drug delivery system based on alginate-chitosan microspheres loaded with icariin in the treatment of ulcerative colitis.
    Wang QS; Wang GF; Zhou J; Gao LN; Cui YL
    Int J Pharm; 2016 Dec; 515(1-2):176-185. PubMed ID: 27713029
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Smart Responsive Quercetin-Conjugated Glycol Chitosan Prodrug Micelles for Treatment of Inflammatory Bowel Diseases.
    Shen C; Zhao L; Du X; Tian J; Yuan Y; Jia M; He Y; Zeng R; Qiao R; Li C
    Mol Pharm; 2021 Mar; 18(3):1419-1430. PubMed ID: 33522827
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Design and in vitro characterization of multistage silicon-PLGA budesonide particles for inflammatory bowel disease.
    Leonard F; Srinivasan S; Liu X; Collnot EM; Ferrari M; Lehr CM; Godin B
    Eur J Pharm Biopharm; 2020 Jun; 151():61-72. PubMed ID: 32283213
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Blockade of PLD2 Ameliorates Intestinal Mucosal Inflammation of Inflammatory Bowel Disease.
    Zhou G; Yu L; Yang W; Wu W; Fang L; Liu Z
    Mediators Inflamm; 2016; 2016():2543070. PubMed ID: 27721573
    [No Abstract]   [Full Text] [Related]  

  • 14. Alginate/chitosan microcapsules for in-situ delivery of the protein, interleukin-1 receptor antagonist (IL-1Ra), for the treatment of dextran sulfate sodium (DSS)-induced colitis in a mouse model.
    Cao J; Cheng J; Xi S; Qi X; Shen S; Ge Y
    Eur J Pharm Biopharm; 2019 Apr; 137():112-121. PubMed ID: 30779979
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Oral infliximab nanomedicines for targeted treatment of inflammatory bowel diseases.
    Mohan LJ; Daly JS; Ryan BM; Ramtoola Z
    Eur J Pharm Sci; 2023 Apr; 183():106379. PubMed ID: 36646154
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Association of polymorphisms in promoter region of TNF-α -238 and -308 with clinical outcomes in patients with immune-mediated inflammatory diseases on anti-TNF therapy.
    Miler M; Nikolac Gabaj N; Ćelap I; Grazio S; Tomašić V; Bišćanin A; Mitrović J; Đerek L; Morović-Vergles J; Vrkić N; Štefanović M
    Rheumatol Int; 2021 Dec; 41(12):2195-2203. PubMed ID: 34623480
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Drug-loaded nanoparticles targeted to the colon with polysaccharide hydrogel reduce colitis in a mouse model.
    Laroui H; Dalmasso G; Nguyen HT; Yan Y; Sitaraman SV; Merlin D
    Gastroenterology; 2010 Mar; 138(3):843-53.e1-2. PubMed ID: 19909746
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Role of the protein annexin A1 on the efficacy of anti-TNF treatment in a murine model of acute colitis.
    de Paula-Silva M; Barrios BE; Macció-Maretto L; Sena AA; Farsky SH; Correa SG; Oliani SM
    Biochem Pharmacol; 2016 Sep; 115():104-13. PubMed ID: 27343762
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Nanoparticles with surface antibody against CD98 and carrying CD98 small interfering RNA reduce colitis in mice.
    Xiao B; Laroui H; Viennois E; Ayyadurai S; Charania MA; Zhang Y; Zhang Z; Baker MT; Zhang B; Gewirtz AT; Merlin D
    Gastroenterology; 2014 May; 146(5):1289-300.e1-19. PubMed ID: 24503126
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Delivery of polysaccharides from Ophiopogon japonicus (OJPs) using OJPs/chitosan/whey protein co-assembled nanoparticles to treat defective intestinal epithelial tight junction barrier.
    Lin C; Kuo TC; Lin JC; Ho YC; Mi FL
    Int J Biol Macromol; 2020 Oct; 160():558-570. PubMed ID: 32464213
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.